Our biotherapeutics research is inspired by patients. Not just those we meet, but all those we never meet who spur us on to discover new medicines for diseases where there are limited treatment options. But our ambition is limitless. And our committed team of scientists are using all their experience and knowledge to forge new research paths, engineer new molecules and do whatever it takes to make sure that no patient is left behind in our search for the next breakthrough.
Patient-centric research approach
Patients are at the heart of our research – right from the beginning. Our patient-centric research approach means we apply disease insights and cutting-edge science to reveal new ways to tackle disease. We also take an open-minded approach to modality, starting with what the patient needs and harnessing biology to reveal insights that inform our decision-making so we can advance novel precision medicine approaches with the potential to create new reference points where limited or no treatment options exist.
Patients first
"This is what drives us. Our team of dedicated scientists have a strong track record of harnessing biology to discover and develop life-changing treatments. And we are investing in cutting-edge technologies to expand and accelerate our drug discovery for the next generation of breakthroughs. We believe that anything is possible. And we stand as a beacon of hope for patients around the world, to deliver the biotherapeutic advances that will transform their lives.” Dr. Andrew Nixon, Global Head Biotherapeutics Discovery, Boehringer Ingelheim
Molecular problem solvers
We have built a deep understanding and expertise in the field of T-cell engagers – a key pillar of our cancer immunology strategy. We also leverage our scientific knowledge and long experience in biotherapeutics discovery to go beyond established approaches to discover novel modalities with the potential to transform the lives of patients. Ultimately, we see ourselves as a group of molecular problem solvers, thinking differently and working differently and with an unwavering commitment to translate disease biology into breakthrough therapies for patients.
Collaboration is key
The work of our own team of biotherapeutics experts is complemented by collaborations with academic organizations, alongside partnerships with biotechs. We believe that by working together we can learn more, do more and achieve more to accelerate the delivery of much-needed new treatments to patients.
Data Science: Revolutionizing research and development with data driven insights
At Boehringer Ingelheim, we are investing into the power of data science with a clear purpose: to revolutionize our research and development, accelerating the journey from scientific discoveries to breakthrough therapies.
